Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells"

Mol Cell Oncol. 2017 Dec 18;5(1):e1403532. doi: 10.1080/23723556.2017.1403532. eCollection 2018.

Abstract

We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models.

Keywords: CML; Cancer stem cells; Imatinib; Leukaemia; Metabolism; OXPHOS; TCA cycle; Tigecycline; Tyrosine kinase inhibitor.

Grant support

Cancer Research UK (C596/A18076); Cancer Research UK (C596/A17196); Kay Kendall Leukaemia Fund (KKLF) (KKL501); Kay Kendall Leukaemia Fund (KKLF) (KKL698).